Rhumbline Advisers Has $6.22 Million Stake in Vericel Co. (NASDAQ:VCEL)

Rhumbline Advisers decreased its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 0.3% in the 1st quarter, Holdings Channel reports. The institutional investor owned 139,324 shares of the biotechnology company’s stock after selling 412 shares during the period. Rhumbline Advisers’ holdings in Vericel were worth $6,217,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Arcadia Investment Management Corp MI acquired a new stake in shares of Vericel during the 4th quarter worth approximately $48,000. GF Fund Management CO. LTD. acquired a new stake in shares of Vericel during the 4th quarter worth approximately $57,000. Smartleaf Asset Management LLC grew its position in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after buying an additional 1,058 shares during the period. Meeder Asset Management Inc. grew its position in shares of Vericel by 8.4% during the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock worth $129,000 after buying an additional 183 shares during the period. Finally, Xponance Inc. acquired a new stake in shares of Vericel during the 4th quarter worth approximately $214,000.

Vericel Stock Performance

Shares of NASDAQ VCEL opened at $44.18 on Thursday. Vericel Co. has a 52-week low of $37.39 and a 52-week high of $63.00. The firm has a 50 day moving average price of $41.34 and a 200 day moving average price of $49.95. The stock has a market cap of $2.22 billion, a P/E ratio of 736.46 and a beta of 1.33.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.14). Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $52.60 million during the quarter, compared to the consensus estimate of $53.86 million. During the same period in the previous year, the firm posted ($0.08) EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Analysts predict that Vericel Co. will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VCEL. Stephens reiterated an “overweight” rating and set a $67.00 price target on shares of Vericel in a research report on Thursday, May 22nd. Truist Financial decreased their price objective on shares of Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a report on Friday, April 11th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. Finally, Wall Street Zen cut shares of Vericel from a “hold” rating to a “sell” rating in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average price target of $61.14.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 24,850 shares of Vericel stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total value of $1,040,966.50. Following the transaction, the chief executive officer now owns 260,354 shares of the company’s stock, valued at approximately $10,906,229.06. The trade was a 8.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 7.20% of the company’s stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.